The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
Open accessAbstract
// Keita Shibuya 1,2,3,* , Masashi Okada 1,* , Shuhei Suzuki 1,4 , Manabu Seino 1,5 , Shizuka Seino 1,2,3,6 , Hiroyuki Takeda 1,4 and Chifumi Kitanaka 1,2,3,6 1 Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan 2 Oncology Research Center, Research Institute for Advanced Molecular Epidemiology, Yamagata University, Yamagata, Japan 3 Global COE program for Medical Sciences, Japan Society for Promotion of Science, Tokyo, Japan 4 Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan 5 Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan 6 Research Institute for Promotion of Medical Sciences, Yamagata University School of Medicine, Yamagata, Japan * These authors contributed equally to this work Correspondence: Chifumi Kitanaka, email: // Keywords : cancer initiating cell, glioma, tumorigenicity, xenograft analysis Received : August 11, 2014 Accepted : November 25, 2014 Published : November 26, 2014 Abstract Increased glucose metabolism is now recognized as an emerging hallmark of cancer. Recent studies have shown that glucose metabolism is even more active in cancer stem cells (CSCs), a rare population of cancer cells with the capacity to self-renew and initiate tumors, and that CSCs are dependent on glycolysis for their survival/growth. However, the role of glucose metabolism in the control of their self-renewal and tumor-initiating capacity per se still remains obscure. Moreover, much remains unknown as to which of the numerous molecules involved in the glucose metabolism is suitable as a target to control CSCs. Here we demonstrate that the facilitative glucose transporter GLUT1 is essential for the maintenance of pancreatic, ovarian, and glioblastoma CSCs. Notably, we found that WZB117, a specific GLUT1 inhibitor, could inhibit the self-renewal and tumor-initiating capacity of the CSCs without compromising their proliferative potential in vitro . In vivo , systemic WZB117 administration inhibited tumor initiation after implantation of CSCs without causing significant adverse events in host animals. Our findings indicate GLUT1-dependent glucose metabolism has a pivotal role not only in the growth and survival of CSCs but also in the maintenance of their stemness and suggest GLUT1 as a promising target for CSC-directed cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Cancer metabolism: current perspectives and future directions
Muñoz-Pinedo, C., El Mjiyad, N., & Ricci, J.-E. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.123 · Cited by 385
Cited by
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L. (2018) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,273
Hypoxia-Modified Cancer Cell Metabolism
Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K., & Forsyth, N. R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00004 · Cited by 503
Chen, W.-H., Luo, G.-F., Lei, Q., Hong, S., Qiu, W.-X., Liu, L.-H., Cheng, S.-X., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.6b06658 · Cited by 367
Metadata
- Authors
- Shibuya, K., Okada, M., Suzuki, S., Seino, M., Seino, S., Takeda, H., & Kitanaka, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-11-26
- Volume
- 6
- Issue
- 2
- Pages
- 651-661
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1568188518
- Cited by
- 188
- References
- 2
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.